Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

被引:7
作者
Cruz-Rico, Graciela [1 ]
Aviles-Salas, Alejandro [1 ]
Popa-Navarro, Xitlally [1 ,2 ]
Lara-Mejia, Luis [1 ]
Catalan, Rodrigo [1 ,2 ]
Sanchez-Reyes, Roberto [1 ]
Lopez-Sanchez, Dennis [1 ]
Cabrera-Miranda, Luis [1 ]
Aquiles Maldonado-Martinez, Hector [1 ]
Samtani-Bassarmal, Suraj [3 ]
Arrieta, Oscar [1 ,2 ]
机构
[1] Inst Nacl Cancerol, Thorac Oncol Unit, Mexico City, DF, Mexico
[2] Inst Nacl Cancerol, Lab Personalized Med, Mexico City, DF, Mexico
[3] Clin Bradford Hill, Med Oncol Serv, Santiago, Chile
关键词
immunotherapy; NSCLC; lung adenocarcinoma; programmed-death receptor ligand 1 (PD-L1); immunohistochemistry; Tumor-infiltrating lymphocytes (TILs) 4; CANCER; MUTATIONS; DOCETAXEL;
D O I
10.3389/pore.2021.597499
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of PD-L1 expression according to the IASLC/ATS/ERS classification and other relevant histological and clinical features. Patients and Methods: PD-L1 expression was assessed by immunohistochemistry (IHC). According to its positivity in tumor cells membrane, we stratified patients in three different tumor proportions score (TPS) cut-off points: a) <1% (negative), b) between 1 and 49%, and c) >= 50%; afterward, we analyzed the association among PD-L1 expression and lung adenocarcinoma (LADC) predominant subtypes, as well as other clinical features. As an exploratory outcome we evaluated if a PD-L1 TPS score >= 15% was useful as a biomarker for determining survival. Results: A total of 240 patients were included to our final analysis. Median age at diagnosis was 65 years (range 23-94 years). A PD-L1 TPS >= 1% was observed in 52.5% of the entire cohort; regarding specific predominant histological patterns, a PD-L1 TPS >= 1 was documented in 31.2% of patients with predominant-lepidic pattern, 46.2% of patients with predominant-acinar pattern, 42.8% of patients with a predominant-papillary pattern, and 68.7% of patients with predominant-solid pattern (p = 0.002). On the other hand, proportion of tumors with PD-L1 TPS >= 50% was not significantly different among adenocarcinoma subtypes. At the univariate survival analysis, a PD-L1 TPS cut-off value of >= 15% was associated with a worse PFS and OS. Conclusion: According to IASLC/ATS/ERS lung adenocarcinoma classification, the predominant-solid pattern is associated with a higher proportion of PD-L1 positive samples, no subtype was identified to be associated with a high (>= 50%) TPS PD-L1.
引用
收藏
页数:9
相关论文
共 41 条
[1]   Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer The PROLUNG Phase 2 Randomized Clinical Trial [J].
Arrieta, Oscar ;
Barron, Feliciano ;
Ramirez-Tirado, Laura Alejandra ;
Zatarain-Barron, Zyanya Lucia ;
Cardona, Andres F. ;
Diaz-Garcia, Diego ;
Yamamoto Ramos, Masao ;
Mota-Vega, Beatriz ;
Carmona, Amir ;
Peralta alvarez, Marco Polo ;
Bautista, Yolanda ;
Aldaco, Fernando ;
Gerson, Raquel ;
Rolfo, Christian ;
Rosell, Rafael .
JAMA ONCOLOGY, 2020, 6 (06) :856-864
[2]   Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox" [J].
Arrieta, Oscar ;
Ramirez-Tirado, Laura-Alejandra ;
Baez-Saldana, Renata ;
Pena-Curiel, Omar ;
Soca-Chafre, Giovanny ;
Macedo-Perez, Eleazar-Omar .
LUNG CANCER, 2015, 90 (02) :161-166
[3]   Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) [J].
Arrieta, Oscar ;
Cardona, Andres F. ;
Martin, Claudio ;
Mas-Lopez, Luis ;
Corrales-Rodriguez, Luis ;
Bramuglia, Guillermo ;
Castillo-Fernandez, Omar ;
Meyerson, Matthew ;
Amieva-Rivera, Eduardo ;
Delia Campos-Parra, Alma ;
Carranza, Hernn ;
Carlos Gomez de la Torre, Juan ;
Powazniak, Yanina ;
Aldaco-Sarvide, Fernando ;
Vargas, Carlos ;
Trigo, Mariana ;
Magallanes-Maciel, Manuel ;
Otero, Jorge ;
Sanchez-Reyes, Roberto ;
Cuello, Mauricio .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (05) :838-843
[4]   Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America [J].
Arrieta, Oscar ;
Felipe Cardona, Andres ;
Federico Bramuglia, Guillermo ;
Gallo, Aly ;
Campos-Parra, Alma D. ;
Serrano, Silvia ;
Castro, Marcelo ;
Aviles, Alejandro ;
Amorin, Edgar ;
Kirchuk, Ricardo ;
Cuello, Mauricio ;
Borbolla, Jose ;
Riemersma, Omar ;
Becerra, Henry ;
Rosell, Rafael .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) :1955-1959
[5]   Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].
Azuma, K. ;
Ota, K. ;
Kawahara, A. ;
Hattori, S. ;
Iwama, E. ;
Harada, T. ;
Matsumoto, K. ;
Takayama, K. ;
Takamori, S. ;
Kage, M. ;
Hoshino, T. ;
Nakanishi, Y. ;
Okamoto, I. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940
[6]   A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies [J].
Batenchuk, Cory ;
Albitar, Maher ;
Zerba, Kim ;
Sudarsanam, Sucha ;
Chizhevsky, Vladislav ;
Jin, Chelsea ;
Burns, Virginia .
JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (12) :1078-1083
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer [J].
Calles, Antonio ;
Liao, Xiaoyun ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Butaney, Mohit ;
Lydon, Christine ;
Dahlberg, Suzanne E. ;
Hodi, F. Stephen ;
Oxnard, Geoffrey R. ;
Jackman, David M. ;
Jaenne, Pasi A. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) :1726-1735
[9]   Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma [J].
Chan, Anthony W. H. ;
Tong, Joanna H. M. ;
Kwan, Johnny S. H. ;
Chow, Chit ;
Chung, Lau Y. ;
Chau, Shuk L. ;
Lung, Raymond W. M. ;
Ng, Calvin S. H. ;
Wan, Innes Y. P. ;
Mok, Tony S. K. ;
To, Ka F. .
MODERN PATHOLOGY, 2018, 31 (09) :1381-1390
[10]   Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].
Chen, Nan ;
Fang, Wenfeng ;
Zhan, Jianhua ;
Hong, Shaodong ;
Tang, Yanna ;
Kang, Shiyang ;
Zhang, Yaxiong ;
He, Xiaobo ;
Zhou, Ting ;
Qin, Tao ;
Huang, Yan ;
Yi, Xianping ;
Zhang, Li .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923